Using Polymers to Enhance Solubility of Poorly Soluble Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Using Polymers to Enhance Solubility of Poorly Soluble Drugs
The authors demonstrate how melt-extrusion and spray-drying methods can help to prepare solid dispersions of poorly soluble drugs using Eudragit polymers.


Pharmaceutical Technology


Materials and methods

Materials. Felodipine for spray-drying was purchased at Shiono Chemical Co. (Tokyo) for melt-extrusion trials in Zhejiang Yiyuan, China. Carbamazepine was a gift from Evonik (Dossenheim, Germany). The authors also used Eudragit E and Eudragit NE30D (Evonik Röhm GmbH, Darmstadt, Germany) and ethanol (Wako Pure Chemical Industries, Osaka, Japan).

Spray-drying. Eight-five percent of 5% Eudragit E PO, 5% Eudragit 30D, and 10% felodipine were dissolved in ethanol (95%). The organic solution contained 14% of solid. Ten percent carbamazepine and 90% Eudragit E PO were dissolved in ethanol (95%) with a solid content of 6%. The spray-drying process was conducted with a Mini Spray-Dryer B-290 (Buech, Tokyo). Operational conditions are described in Table I.

XRPD was carried out on a Mini-Flex, DSC was carried out on a Thermo plus 2–DSC 8230 (Rigaku, Tokyo), and the scanning electronic microscope (SEM) used was a JSM–6360LV (Jeol, Tokyo).

Solubility was measured with high-performance liquid chromatography (HPLC). The drug, the physical mixture, or the spray-dried sample was dispersed in 0.1N hydrochlorid acid (pH 1.2); the dispersion was homogenized with ultra sonic vibration for 10 min and filtered. Solutions with felodipine were diluted with the mobile phase acetonitrile/0.01 M phosphate buffer pH 4.5 (70/30). The wavelength was set to 237 nm and the flow rate was 1 mL/min. Dissolution testing was performed with a paddle apparatus (DT610, Jasco, Tokyo), at a rotation speed of 100 rpm. The authors used 900 mL of 0.1N hydrochlorid acid (pH 1.2) and added samples equivalent to 18 mg of felodipine or 360 mg of carbamazepine. The wavelength was set to 237 nm for felodipine and 285 nm for carbamazepine.

Melt extrusion. Solid dispersions containing felodipine (melting point=145 °C), Eudragit E, and Eudragit NE 30D (10%/85%/5%) and solid dispersion with 10% carbamazepine (190 °C) and 90% Eudragit EPO were prepared by melt extrusion on a twin-screw extruder (Micro 18 GL Pharma, Leistritz, Nürnberg, Germany). The temperature profile of the felodipine sample was between 70°C and 160°C, the screw speed was set at 200rpm, the feeding rate of the solids at 0.7 kg/h and Eudragit NE 30D was dosed with a hose pump. For the carbamazepine sample, the temperature was between 70 °C and 200 °C, the screw speed was 150 rpm, and the feeding rate of the solids was set at 0.5 kg/h. The extrudate was pushed through an orifice, collected on a conveying belt, and granulated. The granules were milled to 250 µm.

XRPD was carried out on an X'Pert Pro MPD Diffraktometer (Panalytical, Almelo, The Netherlands), DSC was done with a Pyris 1 DSC (Perkin Elmer, Waltham, MA). Dissolution testing was performed with a paddle apparatus (DT 700, Erweka, Heusenstamm, Germany) at a rotation speed of 100 rpm. The authors used 500 mL of simulated gastric fluid sine pepsin (SGFsp) at a 1.2 pH and added samples equivalent to 10 mg of felodipine or 200 mg of carbamazepine. The concentration of felodipine was measured with HPLC using acetonitile/phosphate buffer pH 3/methanol 40/40/20 % (v/v/v) as a mobile phase. The wavelength was set to 362 nm and the flow rate was 1 mL/min. The concentration of carbamazepine was measured with an ultraviolet spectrometer at a wavelength of 285 nm.

Preparation of physical mixture. Physical mixtures were prepared by blending the substances for 10 min at 40 rpm in a double-cone mixer (Erweka, Heusenstamm, Germany). For the physical mixture containing Eudragit NE 30D, the dispersions were dried to obtain a solid.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here